Skip to main content

Table 1 Patient characteristics of 124 patients of whom 70 were diagnosed with PCa

From: A positive Real-Time Elastography (RTE) combined with a Prostate Cancer Gene 3 (PCA3) score above 35 convey a high probability of intermediate- or high-risk prostate cancer in patient admitted for primary prostate biopsy

Variable

 

Total (n = 124)

PCa (n = 70)

No PCa (n = 54)

p-value*

PSA

Mean (Median; 95 %CI)

9.1 (7.2; 8.3-9.9)

9.7 (7.7; 8.5-11.0)

8.3 (6.7; 7.2-9.4)

0.090*

PCA3-score

Mean (Median; 95 %CI)

53.1 (33.5; 42.9-63.4)

73.6 (53.5; 57.7-89.6)

26.6 (19.0; 19.9-33-2)

<0.001*

Prostate volume

Mean (Median; 95 %CI)

60.0 (53.0; 54.7-65.4)

49.9 (43.5; 44.7-55.1)

73.2 (66.5; 63.8-82.5)

<0.001*

Age

Mean (Median; 95 %CI)

64.0 (65.1; 62.9-65.2)

64.9 (65.7; 63.5-66.2)

62.9 (63.0; 61.0-64.9)

0.094*

Positive DRE

Number (%)

31 (25 %)

22 (31 %)

9 (17 %)

0,060**

Clinical stage

Number (%)

    

T1c

  

35 (50 %)

  

T2a

  

12 (17 %)

  

T2b

  

6 (9 %)

  

T2c

  

11 (16 %)

  

T3a

  

6 (9 %)

  

Gleason score

Number (%)

    

3 + 2 = 5

  

1 (1 %)

  

3 + 3 = 6

  

21 (26 %)

  

3 + 4 = 7a

  

15 (19 %)

  

4 + 3 = 7b

  

9 (11 %)

  

4 + 4 = 8

  

5 (6 %)

  

4 + 5 = 9

  

4 (5 %)

  

5 + 4 = 9

  

2 (2 %)

  

EAU-risk

Number (%)

    

Low-risk

  

21 (30 %)

  

Intermediate-risk

  

32 (46 %)

  

High-risk

  

17 (24 %)

  
  1. PCa prostate cancer, PSA prostate specific antigen, PCA3 prostate cancer gene 3, DRE digital rectal examination is considered positive if there was suspicion of PCa
  2. *p-value is estimated for the difference of means between the group with PCa and the group without PCa using the t-test
  3. **p-value is estimated for the difference of proportions between the group with PCa and the group without PCa using Chi-square test
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us